Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

New data from digital marketing agency Sagapixel reveals that public interest in the term “GLP-1” has officially surpassed search volume for “Ozempic” — marking a fundamental shift in how patients ...

Research even suggests it can change users' sense of smell, and other common side effects include diarrhoea, nausea, 'sulphur ...

Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...

PolyPeptide Group, the Swiss drug ingredients manufacturer, has exercised an option to increase its revolving credit facility ...

This transition reflects a planned and strategic evolution of MC2 Therapeutics, aligned with the company’s focus on commercial expansion.

Thai healthcare solutions company Zuellig Pharma has announced that Mounjaro (tirzepatide), Eli Lilly’s (NYSE: LLY) ...

A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

"Being linked to 'Ozempic face' inducing changes to the mouth, teeth, gums and surrounding facial structures due to the rapid ...